ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2013
The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review.World journal of gastroenterology · 2021Pooled it
- Effectiveness of Interventions to Increase Colorectal Cancer Screening Among American Indians and Alaska Natives.Preventing chronic disease · 2020Trial
- Is Negative Fecal Immunochemical Test Reassuring? The Cumulative Risk of Colorectal Cancer after Multiple Negative Tests.Gut and liver · 2026Article
- Cost of colorectal cancer screening in two tribal health organizations in Alaska.Cancer causes & control : CCC · 2025Article
- Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer?Gut and liver · 2022Review
- Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force.JAMA · 2021Article
- Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?Therapeutic advances in gastroenterology · 2021Article
- Cancer Screening in Older Adults: Individualized Decision-Making and Communication Strategies.The Medical clinics of North America · 2020Review
- Development of Surface-Enhanced Raman Scattering (SERS)-Based Surface-Corrugated Nanopillars for Biomolecular Detection of Colorectal Cancer.Biosensors · 2020Article
- Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy.Current gastroenterology reports · 2020Review
- The cumulative false-positive rate in colorectal cancer screening: a Markov analysis.European journal of gastroenterology & hepatology · 2020Article
- Observational
- Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- Cancer Models and Real-world Data: Better Together.Journal of the National Cancer Institute · 2016Article
- Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates.American journal of public health · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAnnual colorectal cancer screening with fecal occult blood test (FOBT) is a noninvasive alternative to screening colonoscopy once every 10 years. If false-positive FOBT results are common, then many patients selecting an FOBT regimen will be exposed to the same invasive testing as those selecting a colonoscopy regimen. The objective of this study was to estimate the probability of experiencing a false-positive after receiving annual FOBT screening for 10 years.
methodsMedical records for patients aged 50 to 79 years receiving FOBT screening with Hemoccult Sensa between 1997 and 2009 at Group Health of Washington State captured the date and results of each FOBT, along with subsequent colorectal cancer diagnoses. We used logistic regression to analyze associations between patient characteristics and odds of a positive FOBT with no invasive cancer diagnosis within 1 year (FOBT+, CRC-). We estimated the probability of receiving at least one FOBT+, CRC- result after 10 years of screening.
resultsWe observed 181,950 FOBTs from 94,637 individuals. Older patients, males, and non-White patients were significantly more likely to receive FOBT+, CRC- results (P < 0.001 for all risk factors). After 10 years of annual FOBT, 23.0% [95% confidence interval (CI), 18.2-27.0] will receive at least one FOBT+, CRC- result.
conclusionsMost patients participating in annual FOBT screening for 10 years will not have a positive result, reinforcing the potential value of this regimen as a noninvasive alternative to colonoscopy. IMPACT: Annual stool-based screening is a screening alternative resulting in substantially fewer colonoscopies than once per decade colonoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.